OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, auto-immune diseases and transplantation.
OSE IMMUNOTHERAPEUTICS
Industry:
Biotechnology Medical Medical Device Pharmaceutical
Founded:
2012-01-01
Address:
Nantes, Pays De La Loire, France
Country:
France
Website Url:
http://www.ose-immuno.com
Total Employee:
11+
Status:
Active
Contact:
+33143297857
Email Addresses:
[email protected]
Total Funding:
45.35 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Apple Mobile Web Clips Icon WordPress Content Delivery Network Font Awesome Sitelinks Search Box Yoast WordPress SEO Plugin Yoast SEO Premium
Similar Organizations
Genmedica Therapeutics
Genmedica Therapeutics is a development-stage biotechnology company focused on type 2 diabetes.
ImmunOs Therapeutics
ImmunOs Therapeutics is a clinical-stage biotechnology company.
Osteal Therapeutics
Osteal Therapeutics is a clinical stage specialty pharmaceutical company developing novel treatments for orthopedic infections.
Molecular Partners
Molecular Partners is a clinical-stage biopharmaceutical company.
Neumora Therapeutics
Neumora Therapeutics operates as a clinical-stage biotechnology company.
Oryl Photonics
Oryl Photonics is an innovation-focused photonics company.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Scandinavian Real Hearts
Scandinavian Real Hearts is a medical technology company that develops an artificial heart.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-02-24 | Effimune SAS | Effimune SAS acquired by OSE Immunotherapeutics | N/A |
Investors List
European Investment Bank
European Investment Bank investment in Debt Financing - OSE Immunotherapeutics
Bpifrance
Bpifrance investment in Grant - OSE Immunotherapeutics
Bpifrance
Bpifrance investment in Grant - OSE Immunotherapeutics
Key Employee Changes
Official Site Inspections
http://www.ose-immuno.com Semrush global rank: 1.81 M Semrush visits lastest month: 12.57 K
- Host name: cluster024.hosting.ovh.net
- IP address: 188.165.61.82
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "OSE Immunotherapeutics"
Our Company - Ose Immunotherapeutics - Société de …
OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis …See details»
Ose Immunotherapeutics - Société de biotechnologie …
Nov 4, 2024 OSE Immunotherapeutics Annonce des Résultats Cliniquement Probants et Statistiquement Significatifs de l’Etude de Phase 2 de l’Anticorps Anti-IL7R Lusvertikimab pour le Traitement de la Rectocolite Hémorragique ...See details»
OSE Immunotherapeutics - Crunchbase Company …
OSE Immunotherapeutics SA is a biotechnology business that focuses on the development of immunotherapies for. immune activation and modulation in immuno-oncology and autoimmune illnesses. Tedopi, OSE-172, OSE-703, …See details»
OSE Immunotherapeutics - LinkedIn
OSE Immunotherapeutics, a biotech dedicated to developing first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). • Tedopi® (therapeutic cancer vaccine): Registration Phase 3 ...See details»
OSE Immunotherapeutics - Edison Group
Nov 22, 2024 OSE Immunotherapeutics (OSE) is based in Nantes and Paris in France and is listed on the Euronext Paris exchange. ... OSE has products in development for both immunooncology and immuno-inflammation indications. …See details»
Partnership for first-in-class cancer and CRM …
May 22, 2024 Today Boehringer Ingelheim and OSE Immunotherapeutics SA (OSE), a clinical stage biotech company (ISIN: FR0012127173; Mnemo: OSE), announced a major expansion of their partnership. Two new projects to …See details»
OSE Immunotherapeutics Provides Business and Corporate Update
NANTES, France, May 30, 2024 – 6:15pm CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today provided business and corporate update after …See details»
OSE Immunotherapeutics et Boehringer Ingelheim …
May 22, 2024 OSE Immunotherapeutics est une société de biotechnologie qui développe des produits first-in-class en immuno-oncologie (IO) et immuno-inflammation (I&I). OSE Immunotherapeutics vise à créer une valeur …See details»
OSE Immunotherapeutics Highlights Clinical Portfolio …
Jan 19, 2024 OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology and immuno-inflammation. The Company’s current well …See details»
Four clinical assets - Ose Immuno
OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis ... [email protected]. Paris Office. …See details»
OSE Immunotherapeutics’ Global License to Develop a Novel
Apr 16, 2024 OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the Hart-Scott-Rodino waiting period has expired with respect to its global …See details»
OSE Immunotherapeutics révolutionne le traitement des ... - Le Point
Mar 21, 2024 D ans un monde où les maladies chroniques, auto-immunes, le rejet de greffes et les cancers posent d'énormes défis médicaux, OSE Immunotherapeutics se positionne …See details»
Boehringer Ingelheim and OSE Immunotherapeutics advance
Jul 3, 2024 OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I). The Company’s current well …See details»
Research & Development - Ose Immuno
In parallel, OSE Immunotherapeutics expects to be able to generate further significant value from its two proprietary drug discovery platforms: BiCKI® platform focused on immuno-oncology …See details»
OSE IMMUNO Cours Action OSE, Cotation Bourse Euronext Paris
Le cours de l'action OSE IMMUNO OSE en temps réel sur Boursorama : historique de la cotation sur Euronext Paris, graphique, actualités, consensus des analystes et informations boursièresSee details»
OSE Immunotherapeutics Announces Corporate Update and H1 …
In parallel, OSE Immunotherapeutics expects to be able to generate further significant value from its two proprietary drug discovery platforms: • BiCKI® platform focused on immuno-oncology …See details»
OSE Immunotherapeutics’ Global License to Develop a Novel …
Apr 16, 2024 OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I). The Company’s current …See details»
OSE Immunotherapeutics Announces - Business Wire
Sep 22, 2022 OSE Immunotherapeutics Sylvie Détry [email protected] +33 153 198 757 Investor Relations Thomas Guillot [email protected] +33 607 380 431See details»
2013 11 17 - Communique de presse_FR - Ose Immuno
Paris and Nantes (France), 24 February 2016, 05:40 pm – OSE Pharma (ISIN: FR0012127173; Mnemo: OSE), an immuno-oncology company with a specific immunotherapy activating T …See details»